News und Analysen

Genetic-testing company and researcher 23andMe Holding (NASDAQ: ME) wasn't testing very well with investors on Wednesday. They assertively sold out of the company's shares, to the point where the

If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals

Shares of BioLife Solutions (NASDAQ: BLFS) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock is down more than

Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21%

GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to

Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli

Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300

Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines

One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly

Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it

Only seven years ago, AT&T and General Electric were the eighth- and ninth-largest American companies by market cap, respectively. Today, AT&T has fallen to 81st, while General Electric is 65th. A

As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a

Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings

Image source: The Motley Fool.

Invitae (NYSE: NVTA)Q2 2023 Earnings CallAug 08, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is

Weight loss drugmakers are having an exceptionally strong trading session today. As of 10:32 a.m. ET Tuesday morning, Eli Lilly (NYSE: LLY) was up by a noteworthy 16.7%, Novo Nordisk (NYSE: NVO) was

Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that